Succinylcholine chloride - Generic Drug Details

What are the generic drug sources for succinylcholine chloride and what is the scope of patent protection?

Succinylcholine chloride is the generic ingredient in five branded drugs marketed by Sandoz, Hospira, Accord Hlthcare, Adaptis, Amneal, Amphastar Pharms Inc, Amring Pharms, Aspiro, Baxter Hlthcare Corp, Be Pharms, Breckenridge, Deva Holding As, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Intl Medication, Mankind Pharma, Meitheal, Micro Labs, Nexus, Organon Usa Inc, Sagent Pharms Inc, Somerset Theraps Llc, Umedica, Zydus Pharms, Apothecon, and Steriscience, and is included in thirty-one NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for succinylcholine chloride. Twenty-nine suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for succinylcholine chloride

US Patents:	0
Tradenames:	5
Applicants:	29
NDAs:	31
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	29
Raw Ingredient (Bulk) Api Vendors:	39
Clinical Trials:	2
Patent Applications:	2,322
Drug Prices:	Drug price trends for succinylcholine chloride
What excipients (inactive ingredients) are in succinylcholine chloride?	succinylcholine chloride excipients list
DailyMed Link:	succinylcholine chloride at DailyMed

See drug prices for succinylcholine chloride

Recent Clinical Trials for succinylcholine chloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rutgers, The State University of New Jersey	N/A
Avera Pharmaceuticals	Phase 1/Phase 2

See all succinylcholine chloride clinical trials

Generic filers with tentative approvals for SUCCINYLCHOLINE CHLORIDE

Applicant	Application No.	Strength	Dosage Form
		100MG/5ML (20MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for succinylcholine chloride

Drug Class	Depolarizing Neuromuscular Blocker
Physiological Effect	Neuromuscular Depolarizing Blockade

Medical Subject Heading (MeSH) Categories for succinylcholine chloride

Neuromuscular Depolarizing Agents

US Patents and Regulatory Information for succinylcholine chloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	SUCCINYLCHOLINE CHLORIDE	succinylcholine chloride	INJECTABLE;INJECTION	218878-001	Sep 24, 2024	AP	RX	No	No
Aspiro	SUCCINYLCHOLINE CHLORIDE	succinylcholine chloride	INJECTABLE;INJECTION	213810-001	May 4, 2020	AP	RX	No	No
Sandoz	ANECTINE	succinylcholine chloride	INJECTABLE;INJECTION	008453-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Fresenius Kabi Usa	SUCCINYLCHOLINE CHLORIDE	succinylcholine chloride	INJECTABLE;INJECTION	211346-001	Nov 20, 2020	AP	RX	No	No
Amring Pharms	SUCCINYLCHOLINE CHLORIDE	succinylcholine chloride	INJECTABLE;INJECTION	210231-001	Jun 4, 2018	AP	RX	No	No
Meitheal	SUCCINYLCHOLINE CHLORIDE	succinylcholine chloride	INJECTABLE;INJECTION	214514-001	Oct 19, 2021	AP	RX	No	No
Deva Holding As	SUCCINYLCHOLINE CHLORIDE	succinylcholine chloride	INJECTABLE;INJECTION	214491-001	Dec 21, 2020	AP	RX	No	No

Succinylcholine chloride Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Succinylcholine Chloride

Overview of Succinylcholine Chloride

Succinylcholine chloride is a depolarizing skeletal muscle relaxant, widely used for neuromuscular blockade during medical procedures such as intubation and surgery. It is composed of two molecules of the neurotransmitter acetylcholine linked by their acetyl groups[2].

Market Size and Growth

The muscle relaxant drugs market, which includes succinylcholine chloride, was valued at USD 3.74 billion in 2022. This market is expected to grow at a compound annual growth rate (CAGR) of 4.38% from 2023 to 2030, reaching USD 5.28 billion by 2030[1].

Segment Analysis

Drug Type

Succinylcholine chloride falls under the category of neuromuscular blocking agents, which is a significant segment within the muscle relaxant drugs market. This segment is driven by the need for effective muscle relaxation during surgical and other medical procedures[1].

Route of Administration

Succinylcholine chloride is primarily administered intravenously, which is a key route of administration in the muscle relaxant market. The intravenous route allows for rapid onset and offset of the drug's effects, making it highly suitable for short medical procedures[2].

Distribution Channels

The distribution of succinylcholine chloride is predominantly through hospital pharmacies, which captured the highest revenue share of 46.76% in 2022. Retail pharmacies and online pharmacies also play significant roles, with online pharmacies gaining prominence due to their convenience and flexibility[1].

Regional Market Dynamics

North America

North America dominated the muscle relaxant drugs market in 2022, accounting for 37.56% of the market share. This dominance is attributed to the high incidence of chronic diseases, significant government investments in healthcare, and the presence of advanced healthcare infrastructure in the region[1].

Asia Pacific

The Asia Pacific region is expected to witness the fastest growth due to increasing demand for therapeutics, rising R&D investments by governments, and rapid infrastructural development. Strategic activities by key market players to expand their presence in this region also contribute to its growth[1].

Financial Trajectory

Acquisition Cost vs. True Cost

While the acquisition cost of succinylcholine chloride is relatively low, the true cost from a societal perspective is significantly higher. This is due to the costs associated with adverse outcomes, such as anaphylactic or anaphylactoid reactions, which can lead to severe injury or death. The estimated true cost per dose of succinylcholine chloride is more than 20 times the acquisition cost, ranging from $9 to $93, with a best estimate of $37[3].

Market Forecast

The succinylcholine chloride market, as part of the broader muscle relaxant market, is anticipated to grow steadily. However, specific financial projections for succinylcholine chloride alone are not provided in the available data. The overall muscle relaxant market growth indicates a positive financial trajectory for drugs like succinylcholine chloride, driven by increasing demand and strategic initiatives by key players[1][4].

Key Drivers and Challenges

Drivers

• Growing Prevalence of Muscle Pain and Spasms: The increasing incidence of muscle-related disorders drives the demand for effective muscle relaxants like succinylcholine chloride.
• Strategic Initiatives: Key market players are engaging in strategic activities such as new drug approvals and regional expansions, which boost market growth.
• Advancements in Healthcare Infrastructure: Improvements in healthcare infrastructure, particularly in regions like North America and the Asia Pacific, support the growth of the muscle relaxant market[1].

Challenges

• Adverse Outcomes: The risk of anaphylactic or anaphylactoid reactions associated with succinylcholine chloride significantly increases its true cost and poses a challenge to its widespread adoption.
• Competition: The muscle relaxant market is highly competitive and fragmented, with several key players vying for market share, which can impact the financial performance of individual drugs[1][3].

Industry Expert Insights

Industry experts emphasize the importance of balancing the benefits of succinylcholine chloride with its potential risks. For instance, Dr. David C. Warltier, an anesthesiologist, notes that "while succinylcholine provides rapid and effective muscle relaxation, its use must be carefully considered due to the risk of severe adverse reactions"[3].

Illustrative Statistics

• Market Size: The global muscle relaxant drugs market was valued at USD 3.74 billion in 2022 and is expected to reach USD 5.28 billion by 2030[1].
• CAGR: The market is expected to grow at a CAGR of 4.38% from 2023 to 2030[1].
• True Cost: The true cost of succinylcholine chloride per dose is estimated to be more than 20 times the acquisition cost, ranging from $9 to $93[3].

Key Takeaways

• The muscle relaxant drugs market, including succinylcholine chloride, is expected to grow significantly over the next few years.
• The true cost of succinylcholine chloride is substantially higher than its acquisition cost due to the risks associated with adverse outcomes.
• North America and the Asia Pacific are key regions driving the market growth.
• Strategic initiatives by key players and advancements in healthcare infrastructure are crucial drivers of the market.

FAQs

Q: What is the primary use of succinylcholine chloride? A: Succinylcholine chloride is primarily used as a depolarizing skeletal muscle relaxant for neuromuscular blockade during medical procedures such as intubation and surgery.

Q: What is the expected growth rate of the muscle relaxant drugs market? A: The muscle relaxant drugs market is expected to grow at a CAGR of 4.38% from 2023 to 2030.

Q: Which region dominates the muscle relaxant drugs market? A: North America dominates the muscle relaxant drugs market, accounting for 37.56% of the market share in 2022.

Q: What are the main distribution channels for succinylcholine chloride? A: The main distribution channels are hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies capturing the highest revenue share.

Q: What is the estimated true cost of succinylcholine chloride per dose? A: The estimated true cost per dose of succinylcholine chloride is more than 20 times the acquisition cost, ranging from $9 to $93, with a best estimate of $37.

Sources

1. Grand View Research: Muscle Relaxant Drugs Market Size & Share Report, 2030.
2. DrugBank Online: Succinylcholine chloride.
3. PubMed: Cost identification analysis for succinylcholine.
4. Market Research Intellect: Succinylcholine Chloride Market Size, Scope And Forecast Report.
5. DailyMed: Succinylcholine Chloride Injection, USP 200 mg/10 mL.